Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES
Advanced Enzyme Technologies — Q4 FY2019 Earnings Presentation
14 slides from Advanced Enzyme Technologies's earnings presentation, May 27, 2019
Slide 1: Advanced Enzyme Technologies Limited Earnings Presentation May 2019
Advanced Enzyme Technologies Limited Earning Presentation | May 2019
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: Company Overview: What are enzymes?
Company Overview What are enzymes? Enzymes are natural protein molecules that act as catalysts within living cells, produced by all living organisms. Function as specialized catalysts and accelerate the pace of biochemical reactions. Advanced uses enzymes to replace chemicals in, and improve efficie
Slide 4: Advanced Enzyme Technologies Limited – A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star Revenue (₹ mn) 1st Indian enzyme company Highest market share in India Listed integrated enzyme player globally 4,196 2nd 2nd Amongst Top 15 Global Enzyme Companies 2,321 Manufacturing Units – 7 R&D Units – 7 FY 15 FY 19 India - 5 USA - 2 I
Slide 5: Results Summary – Q4FY19
Results Summary – Q4FY19 *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,086 1,104 484 497 335 283 Q4FY18 Q4FY19 Q4FY18 Q4FY19 Q4FY18 Q4FY19 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Bio-Processing -24% (18%) (11%) 7% 3% Q4FY19 121 832 121 Q4FY18 136 779 118 Note: 1.. On Consolidated Ba
Slide 6: Results Summary – FY19
Results Summary – FY19 *Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 4,196 1,159 1,819 3,957 1,640 936 FY18 FY19 FY18 FY19 FY18 FY19 Revenue Breakup ₹ in Million *YoY Growth Animal HC Human HC Industrial Processing -24% (1%) 10% (1%) 9% FY19 493 3,133 482 FY18 498 2,860 444 Note: 1.. On Consolidated Basi
Slide 7: Revenue Split – Q4FY18 vs. Q4FY19
Revenue Split – Q4FY18 vs. Q4FY19 Q4FY19 Q4FY18 Segmental Revenue Split (%) Segmental Revenue Split (%) 11% 11% 12% 13% 78% 75% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 1% 1% 5% 2% 48% 50% 43% 43% 3% 4% Asia (ex
Slide 8: Revenue Split – FY18 vs FY19
Revenue Split – FY18 vs FY19 FY19 FY18 Segmental Revenue Split (%) Segmental Revenue Split (%) 12% 12% 12% 13% 76% 75% Animal HC Human HC Bio-Processing Animal HC Human HC Bio-Processing Geographical Revenue Split (%) Geographical Revenue Split (%) 2% 1% 4% 4% 47% 50% 41% 45% 3% 3% Asia (ex- India)
Slide 9: Profit & Loss (Consolidated) – Q4FY19 & FY19
Profit & Loss (Consolidated) – Q4FY19 & FY19 ₹ in Million except per share data Q4FY19 Q3FY19 Q4FY18 FY19 FY18 Particulars Y-o-Y (%) Y-o-Y (%) Audited Unaudited Audited Audited Audited Income from Operations 1,104 1,017 1,086 2% 4,196 3,957 6% Expenses 660 654 649 2% 2,588 2,500 4% Profit from Opera
Slide 10: Balance Sheet (Consolidated) – FY19
Balance Sheet (Consolidated) – FY19 ₹ in Million FY19 FY18 Particulars Audited Audited Assets Property, plant and equipment 1,618 1,667 Capital work-in-progress 105 105 Intangible assets 622 662 Goodwill 2,715 2,584 Other non-current assets 183 143 Current assets 2,821 2,107 Assets held for sale 48
Slide 11: Strong Financial Performance – FY19
Strong Financial Performance – FY19 ₹ in Million Revenue from Operations 2,500 EBIDTA & EBIDTA Margin (%) 50% 47% 45% 48% 4,196 3,957 2,000 45% 42% 46% 3,431 1,870 2,938 1,500 42% 1,654 44% 1,534 2,321 1,000 1,389 42% 931 40% 500 38% 0 36% FY 15 FY 16 FY 17 FY 18 FY 19 FY 15 FY 16 FY 17 FY 18 FY19 E
Slide 12: Strong Financial Performance – FY19
Strong Financial Performance – FY19 Net Working Capital (Days) Net Worth (₹ mn) 128 6,788 119 5,591 4,640 112 110 108 2,781 2,120 FY 15 FY 16 FY 17 FY 18 FY 19 FY 15 FY 16 FY 17 FY 18 FY 19 ROE (%) & ROCE (%) Net Debt to Equity (x) 34% 0.5 26% 27% 27% 26% 0.4 28% 24% 19% 18% 19% 0.1 0.01 0.02 FY 15
Slide 13: Shareholder Information
Shareholder Information Stock Data (As on 24th May 2019) Top 5 Institutional Holders (As on 17th May 2019) Institutions OS (%) Market Capitalization (₹) 22,429 mn Orbimed Asia Mauritius Limited 12.10 Shares Outstanding 111.6 mn HDFC Asset Management Co. Ltd. 6.23 Free Float 36.90% Reliance Capital T
Slide 14: Thank You
IR Contact: Supreet Singh Jossan Email: investor.realtions@advancedenzymes.com Thank You Advanced Enzyme Technologies Limited 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi, Thane (W) 400 604, India Tel.: +91-22-4170 3200 | Fax: + 91-22-25835159 Web: www.advancedenzymes.com
Advanced Enzyme Technologies — Q4 FY2019 Earnings Presentation on 6ix